STAT+: OpenEvidence will add FDA-cleared AI to detect heart disease

OpenEvidence announced plans to commercialize an AI tool designed to detect heart disease from electrocardiograms (EKGs) on March 18, 2024. The company, co-founded by Pierre Elias, aims to integrate this FDA-cleared technology into clinical practice, potentially improving early diagnosis and patient outcomes. Elias, previously recognized by STAT as a promising young researcher in 2020, has been developing this AI solution for several years. The technology leverages machine learning algorithms to analyze complex EKG data, identifying subtle patterns indicative of cardiac conditions that might be missed by traditional methods. OpenEvidence's strategy involves partnering with healthcare providers and potentially integrating the AI into existing EKG monitoring systems. The company believes this approach will accelerate the adoption of AI in cardiology and enhance the diagnostic capabilities of physicians. The development signifies a growing trend of AI-powered medical devices receiving regulatory approval and moving towards widespread clinical use, addressing critical needs in cardiovascular disease detection.